Exosomal Liquid Biopsy: Early Gastric Cancer Detection
- A microRNA (miRNA)-based liquid biopsy, the destinex assay, demonstrates high accuracy in identifying gastric cancer (GC), even in early stages, according to research published in JAMA Surgery.
- Gastric cancer remains the third leading cause of cancer-related deaths globally, largely due to late-stage diagnoses.
- Current blood-based tumor markers, such as carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, and CA125, lack the necessary sensitivity and specificity for early-stage detection.
Destinex Assay: A Novel Liquid Biopsy for Early Gastric Cancer Detection
Table of Contents
A microRNA (miRNA)-based liquid biopsy, the destinex assay, demonstrates high accuracy in identifying gastric cancer (GC), even in early stages, according to research published in JAMA Surgery. Researchers,led by Silei Sui, M.D., Ph.D., from city of Hope, aimed to address the critical need for cost-effective and minimally invasive early GC detection, notably in regions wiht low GC prevalence.
The Challenge of Gastric cancer Diagnosis
Gastric cancer remains the third leading cause of cancer-related deaths globally, largely due to late-stage diagnoses. Patients diagnosed at advanced stages often face poor prognoses and are ineligible for curative treatment. while mass endoscopic screening programs have improved outcomes in high-incidence countries like Japan and South Korea, these programs are invasive, costly, and impractical for widespread implementation in lower-prevalence areas.
Current blood-based tumor markers, such as carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, and CA125, lack the necessary sensitivity and specificity for early-stage detection. Tissue biopsy, the current gold standard, is invasive, carries procedural risks, and can be affected by tumor heterogeneity and sampling errors. Repeat biopsies for monitoring are frequently enough impractical.
Liquid Biopsies and the Promise of miRNAs
Liquid biopsies, analyzing circulating tumor DNA (ctDNA), circulating tumor cells, and exosomal RNA, offer a minimally invasive alternative. while ctDNA is highly specific, its sensitivity can be limited in early disease. Exosomal miRNAs, encapsulated in vesicles secreted by tumor cells, offer both stability and tissue specificity, making them promising biomarkers for early detection.
Growth and Validation of the Destinex Assay
The DESTINEX multicenter case-control study developed a complete miRNA-based liquid biopsy combining cell-free and exosomal miRNA signatures. The study, conducted across major referral centers in Japan and South Korea, analyzed 809 GC specimens from 480 patients between 2016 and 2020, progressing through discovery, training, validation, and evaluation phases.
Genome-wide transcriptomic profiling led to an initial panel of 8 cell-free miRNAs and 10 exosomal miRNAs. machine learning algorithms were used to create a 17-miRNA GC signature, effectively distinguishing between individuals with and without gastric cancer. This signature achieved robust area Under the Curve (AUC) values of 96.3% (95% CI, 94.3%-98.4%) in the training cohort and 95.3% (95% CI, 92.8%-97.9%) in the autonomous validation cohort.
Researchers then focused on creating a more clinically feasible and cost-effective assay, identifying 5 overlapping miRNAs (miR-21-3p, miR-21-5p, miR-215-5p, miR-27a-3p, and miR-95-3p) common to both cell-free and exosomal panels. This led to the development of the final 10-miRNA signature, named Destinex.
Destinex Performance and Specificity
The Destinex assay demonstrated comparable diagnostic performance to the 17-miRNA signature, achieving an AUC of 95.8% in the training cohort and 94.8% in the validation cohort. Importantly, Destinex proved highly effective in identifying early-stage (pT1) GC, with an impressive AUC of 96.8% (95% CI, 93.5%-100%). Post-surgery serum specimens showed significantly decreased expression levels of these miRNA markers, confirming their tumor-specific origin.
Destinex also exhibited high specificity for GC, outperforming its diagnostic value in other gastrointestinal cancers, including colorectal cancer, pancreatic ductal adenocarcinoma, esophageal squamous cell carcinoma, intrahepatic cholangiocarcinoma, and hepatocellular carcinoma.
Clinical and Economic Implications
From a managed care perspective, Destinex could enable earlier detection in asymptomatic or high-risk populations, potentially shifting diagnoses toward curable stages.its potential as a cost-effective screening tool could reduce reliance on invasive endoscopy in low-prevalence settings, lowering procedural costs and patient burden.
Early detection can reduce downstream costs associated with advanced disease management,hospitalizations,and palliative care. The assay may also support precision oncology workflows by integrating with guideline-concordant biomarker testing and improve care equity by offering a scalable, blood-based test deployable in community settings with limited access to advanced endoscopy.
Future Directions
Real-world implementation of Destinex will require validation in multinational, diverse populations. Health economic modeling is crucial to demonstrate cost-effectiveness and facilitate integration into clinical pathways and payer coverage policies.